Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Antonio Pea

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0509-6756; OpenAlex author ID A5007326963. Sources: OpenAlex.

Their work

Papers
25 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
147
Papers, trials and grants by year

2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 4 papers · 2022: 4 papers · 2023: 4 papers · 2024: 2 papers · 2025: 4 papers · 2026: 2 papers

Papers 25

  1. Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas. Co-author DOI 10.1038/s41467-026-69762-w↗
  2. Morphologic Characterization of Pancreatic Ductal Adenocarcinoma following Post-neoadjuvant Pancreatectomy and Clinical Value of Intratumor Heterogeneity. Co-author DOI 10.1097/sla.0000000000006565↗
  3. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  4. Chemotherapy enhances HMGA1 secretion through the mutant p53-CK2 axis in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1038/s41419-025-08082-1↗
  5. Resection to Exploration Ratios and Associated Outcomes in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006197↗
  6. Surgical and Oncological Outcomes of Minimally Invasive Left Pancreatectomy for Pancreatic Cancer: Robotic vs. Laparoscopic Approach. Co-author DOI 10.3390/curroncol32070376↗
  7. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  8. Integrating metabolic profiling of pancreatic juice with transcriptomic analysis of pancreatic cancer tissue identifies distinct clinical subgroups. Co-author DOI 10.3389/fonc.2024.1405612↗
  9. Contact system and intrinsic pathway activation in patients with advanced pancreatic cancer: a prospective cohort study. Co-author DOI 10.1016/j.jtha.2023.06.009↗
  10. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. Co-author DOI 10.1016/j.modpat.2023.100251↗
  11. A dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2022.11.015↗
  12. The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005050↗
  13. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metas… Co-author DOI 10.1007/s00428-021-03205-3↗
  14. Loss of FGFR4 promotes the malignant phenotype of PDAC. Co-author DOI 10.1038/s41388-022-02432-5↗
  15. Circulating tumour DNA: a challenging innovation to develop "precision onco-surgery" in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-022-01745-2↗
  16. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  17. Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward. Co-author DOI 10.1053/j.gastro.2021.06.080↗
  18. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. Co-author DOI 10.1200/jco.20.03238↗
  19. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Co-author DOI 10.3390/cancers13133119↗
  20. Molecular Subtyping and Precision Medicine for Pancreatic Cancer. Co-author DOI 10.3390/jcm10010149↗
  21. Combinatorial Effect of Magnetic Field and Radiotherapy in PDAC Organoids: A Pilot Study. Co-author DOI 10.3390/biomedicines8120609↗
  22. Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. First author DOI 10.1038/s41379-018-0183-7↗
  23. Ablation treatments in unresectable pancreatic cancer. Co-author DOI 10.23736/s0026-4733.18.07881-1↗
  24. Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer. First author DOI 10.1007/s00464-018-6217-x↗
  25. Histo-molecular oncogenesis of pancreatic cancer: From precancerous lesions to invasive ductal adenocarcinoma. First author DOI 10.4251/wjgo.v10.i10.317↗

Closest collaborators

The 25 strongest of 147 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Roberto Salvia · 16 shared papers, 2019–2026 · strength 2.42
  2. Aldo Scarpa Scarpa · 15 shared papers, 2018–2026 · strength 2.04
  3. Claudio Luchini · 12 shared papers, 2018–2026 · strength 1.76
  4. Giuseppe Malleo · 9 shared papers, 2021–2026 · strength 1.51
  5. Rita Teresa Lawlor · 10 shared papers, 2018–2026 · strength 1.24
  6. Salvatore Paiella · 7 shared papers, 2019–2026 · strength 1.22
  7. Alessandro Esposito · 4 shared papers, 2023–2026 · strength 0.90
  8. Gabriella Lionetto Lionetto · 4 shared papers, 2023–2026 · strength 0.90
  9. David Kuang-Fu Chang · 6 shared papers, 2021–2025 · strength 0.84
  10. Matteo De Pastena · 4 shared papers, 2019–2026 · strength 0.82
  11. Claudio Bassi · 7 shared papers, 2019–2023 · strength 0.82
  12. Fabio Casciani · 3 shared papers, 2025–2026 · strength 0.73
  13. Vincenzo Corbo · 6 shared papers, 2020–2025 · strength 0.70
  14. Michèle Milella · 6 shared papers, 2021–2023 · strength 0.67
  15. Paola Mattiolo · 4 shared papers, 2021–2026 · strength 0.63
  16. Alessandra Pulvirenti · 3 shared papers, 2023–2026 · strength 0.52
  17. Nigel Balfour Jamieson · 3 shared papers, 2023–2026 · strength 0.52
  18. Andrew Victor Biankin · 4 shared papers, 2021–2023 · strength 0.51
  19. Andrea Mafficini · 4 shared papers, 2021–2025 · strength 0.51
  20. Fieke E. M. Froeling · 3 shared papers, 2021–2026 · strength 0.49
  21. Massimo Donadelli · 2 shared papers, 2025–2026 · strength 0.43
  22. Carlotta Franzina · 2 shared papers, 2025–2026 · strength 0.40
  23. Lodewijk A.A. Brosens · 3 shared papers, 2021–2025 · strength 0.39
  24. Raffaella Casolino · 3 shared papers, 2021 · strength 0.38
  25. Matteo Fassan · 2 shared papers, 2023–2026 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.